MitoCatch Delivers Healthy Mitochondria to Diseased Cells with Precision Technology

MitoCatch Targets Precision Delivery of Healthy Mitochondria to Diseased Cells Scientists have developed a novel system capable of delivering healthy mitochondria to specific cell types affected by disease, addressing a major limitation in mitochondrial transplantation therapies. The approach, named MitoCatch, uses engineered protein binders to guide mitochondria into damaged cells with precision, offering potential treatment strategies for conditions linked to mitochondrial dysfunction. Mitochondrial dysfunction plays a role in numerous diseases that currently lack effective treatments, including neurodegenerative disorders such as Parkinson’s and Alzheimer’s, optic nerve atrophy, and heart failure. Even as transplanting healthy mitochondria has been explored as a therapeutic strategy, existing methods have struggled to deliver them accurately and efficiently to the cells that need them most. MitoCatch overcomes this challenge through three distinct strategies. MitoCatch-C involves placing binders on the cell surface to capture mitochondria. MitoCatch-M attaches binders directly to mitochondria. MitoCatch-Bi uses bispecific binders that link mitochondria directly to target cell membranes. By adjusting the affinity of these binders and combining multiple binding interactions, researchers achieved efficient, cell-type-specific delivery in both human and mouse models. The system enables donor mitochondria to be internalized by target cells, exposed to the cytosol, and to undergo natural processes of movement, fusion, and fission inside the cell. Researchers demonstrated targeted delivery to retinal cells, neurons, and cardiac, endothelial, and immune cells. In preclinical testing, transplanted mitochondria promoted the survival of damaged neurons from a patient with optic nerve atrophy in vitro and after neuronal injury in mice in vivo. By solving the long-standing challenge of directing mitochondria to disease-affected cell types, MitoCatch creates new opportunities for both basic research and the development of treatments for a range of disorders associated with mitochondrial failure. The technology represents a significant advancement in the field of cellular therapy, providing a method to deliver one of the cell’s most vital components exactly where it is needed.